Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...

Civica will start selling the medicine for patients in the United States after completing development work and clinical ...

President and CEO Ned McCoy shared with Becker's some of the company's key objectives for the year, including the launch of some of the first medications from its Petersburg, Va.-based plant, the ...

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

Biocon said that its wholly owned subsidiary, Biocon Biologics announced strategic collaboration agreement with Civica, Inc. to expand access, affordability of Insulin Aspart in the United States.

Biocon Biologics Ltd and Civica, Inc. today announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States.

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

The 26-week, open-label clinical trial randomized 230 pediatric subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA) in combination with ...

The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...